Segment Information (Tables)

6 Months Ended

Jun. 30, 2026

Schedule of Sales by Significant Product Group

The following table presents information about our reportable segments, reconciled to consolidated totals:


	Three Months Ended June 30,				Six Months Ended June 30,
($ in millions)	2026		2025		2026		2025
Net sales:
Proprietary Products	$	722.6	$	619.8	$	1,416.9	$	1,182.8
West Vantage	149.7		146.7		300.3		281.7

Consolidated net sales	$	872.3	$	766.5	$	1,717.2	$	1,464.5

Schedule of Segment Financial Information

The following tables provide summarized financial information for our two reportable segments and corporate and unallocated:


($ in millions)	June 30, 2026		December 31, 2025
Assets
Proprietary Products	$	2,909.2	$	2,987.0
West Vantage	717.7		718.1
Corporate and Unallocated (1)	449.5		564.9
Total consolidated	$	4,076.4	$	4,270.0

(1) Corporate and unallocated assets primarily include investments in affiliated companies, cash and cash equivalents, property, plant and equipment used in our corporate operations and deferred income taxes.


($ in millions)	Three Months Ended June 30,				Six Months Ended June 30,
Depreciation and Amortization	2026		2025		2026		2025
Proprietary Products	$	36.3	$	33.7	$	72.7	$	66.4
West Vantage	9.2		6.8		17.2		13.2
Corporate and Unallocated	0.7		0.9		1.5		1.8
Total consolidated	$	46.2	$	41.4	$	91.4	$	81.4


($ in millions)	Three Months Ended June 30,				Six Months Ended June 30,
Capital Expenditures	2026		2025		2026		2025
Proprietary Products	$	35.4	$	48.5	$	71.9	$	100.4
West Vantage	5.1		25.5		10.7		43.6
Corporate and Unallocated	2.7		1.2		3.3		2.5
Total consolidated	$	43.2	$	75.2	$	85.9	$	146.5

The following table provides summarized financial information for our segments:


	Three months ended June 30, 2026						Three months ended June 30, 2025
($ in millions)	Proprietary Products		West Vantage		Total		Proprietary Products		West Vantage		Total
Net sales	$	722.6	$	149.7	$	872.3	$	619.8	$	146.7	$	766.5
Cost of goods and services sold	414.6		128.5				371.5		121.1
Research and development	19.7		—				19.1		—
Selling, general and administrative expenses	69.5		8.3				61.5		7.0
Other segment expense (income)(1)	6.9		—				6.0		0.8
Segment operating profit	$	211.9	$	12.9	$	224.8	$	161.7	$	17.8	$	179.5
Reconciliation of profit or loss:
Stock-based compensation					(10.9)						(7.4)
Corporate general costs(2)					(16.5)						(16.8)
Unallocated items:
Restructuring and other charges(3)					(1.5)						(1.6)

M&A activities, including SmartDose® 3.5mL sale(4)					(6.4)						—
Cost-method investment activity(5)					(3.5)						—


Other(7)					(6.9)						—
Total consolidated operating profit					179.1						153.7
Interest (income) expense and other nonoperating expense (income), net					(1.0)						(3.3)
Income before income taxes and equity in net income of affiliated companies					$	180.1					$	157.0


	Six Months June 30, 2026						Six months ended June 30, 2025
($ in millions)	Proprietary Products		West Vantage		Total		Proprietary Products		West Vantage		Total
Net sales	$	1,416.9	$	300.3	$	1,717.2	$	1,182.8	$	281.7	$	1,464.5
Cost of goods and services sold	835.8		255.8				724.3		234.4
Research and development	35.5		—				35.4		—
Selling, general and administrative expenses	134.5		16.1				121.8		14.6
Other segment expense (income)(1)	10.0		(0.1)				9.0		1.4
Segment operating profit	$	401.1	$	28.5	$	429.6	$	292.3	$	31.3	$	323.6
Reconciliation of profit or loss:
Stock-based compensation					(17.5)						(8.7)
Corporate general costs(2)					(33.7)						(34.6)
Unallocated items:
Restructuring and related charges(3)					(2.9)						(19.4)

M&A activities, including SmartDose® 3.5mL sale(4)					(8.3)						—
Cost-method investment activity(5)					(3.5)						—

Amortization of acquisition-related intangible assets(6)					—						(0.2)
Other(7)					(7.5)						—

Total consolidated operating profit					356.2						260.7
Interest (income) expense and other nonoperating expense (income), net					(4.0)						(6.8)
Income before income taxes and equity in net income of affiliated companies					$	360.2					$	267.5

(1) Other segment expense (income) primarily includes foreign exchange transaction gains and losses, adjustments to contingent consideration and (gain) loss on oil hedges attributable to the segments during the three and six months ended June 30, 2026 and 2025.

(2) Corporate general costs include executive and director compensation, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments.

(3) During the three and six months ended June 30, 2026, the Company recorded pre-tax charges of $1.5 million and $2.9 million, respectively, related to our two existing restructuring programs: (i) $1.0 million and $1.9 million, respectively, within other expense (income), related to acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $0.5 million and $1.0 million, respectively, within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries. During the three and six months ended June 30, 2025, the Company recorded pre-tax charges of $1.6 million and $19.4 million, respectively, related to our two existing restructuring programs: (i) $0.2 million and $16.6 million, respectively, within other expense (income), related to severance, acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $1.4 million and $2.8 million, respectively, within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries.

(4) During the three and six months ended June 30, 2026, the Company recorded pre-tax charges of $6.4 million and $8.3 million, respectively, related to M&A activities, including the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie. The Company recorded $1.3 million and $2.2 million, respectively, of the charges within other expense (income), related to employee benefit costs in connection with the sale agreement. The Company recorded the remaining $5.1 million and $6.1 million, respectively, within selling, general and administrative expenses, relating to professional services in connection with the sale agreement and other M&A activities.

(5) During the three and six months ended June 30, 2026, the Company recorded cost-method investment impairment charges of $3.5 million within other expense (income).

(6) During the three and six months ended June 30, 2025, we recorded $0.0 million and $0.2 million, respectively, of amortization expense within selling, general and administrative expenses associated with an intangible asset acquired during the second quarter of 2020.

(7) Other includes nonrecurring professional fees associated with various items including certain legal matters and our cybersecurity incident from May 2026. These charges are recorded within selling, general and administrative expenses.

- Definition

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

WEST PHARMACEUTICAL SERVICES INC 10-Q